细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5331人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Clin Cancer Res：细胞周期蛋白D1依赖性转录程序可预测套细胞淋巴瘤患者的临床预后, objectType=article, longId=202044, objectId=4c65202044da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c65202044da, replyNumber=0, likeNumber=90, createdTime=2021-01-28, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c65202044da, moduleTitle=Clin Cancer Res：细胞周期蛋白D1依赖性转录程序可预测套细胞淋巴瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c65202044da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702636, encodeId=e2031e0263619, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：套细胞淋巴瘤亚型的基因组学和表观遗传学分析, objectType=article, longId=196924, objectId=620c196924ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=620c196924ce, replyNumber=0, likeNumber=69, createdTime=2020-11-03, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=620c196924ce, moduleTitle=Blood：套细胞淋巴瘤亚型的基因组学和表观遗传学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=620c196924ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702667, encodeId=27001e02667fa, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=68, createdTime=2021-12-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702628, encodeId=16a51e02628cf, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析, objectType=article, longId=194670, objectId=14c31946e072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14c31946e072, replyNumber=0, likeNumber=83, createdTime=2020-11-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14c31946e072, moduleTitle=Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14c31946e072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702660, encodeId=b0631e026600c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：20号染色体缺失是乳房植入物相关间变性大细胞淋巴瘤的特征！, objectType=article, longId=205383, objectId=4eaf20538347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eaf20538347, replyNumber=0, likeNumber=94, createdTime=2021-09-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eaf20538347, moduleTitle=Blood：20号染色体缺失是乳房植入物相关间变性大细胞淋巴瘤的特征！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eaf20538347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702637, encodeId=1bd91e0263787, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防, objectType=article, longId=196933, objectId=99aa19693328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99aa19693328, replyNumber=0, likeNumber=78, createdTime=2021-01-15, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99aa19693328, moduleTitle=Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99aa19693328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702653, encodeId=adae1e02653ef, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施, objectType=article, longId=201786, objectId=f16c201e869b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f16c201e869b, replyNumber=0, likeNumber=102, createdTime=2021-03-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f16c201e869b, moduleTitle=Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f16c201e869b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702638, encodeId=16b71e02638f0, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, objectType=article, longId=197011, objectId=7c6419e01122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6419e01122, replyNumber=0, likeNumber=75, createdTime=2020-12-28, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6419e01122, moduleTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6419e01122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702641, encodeId=240a1e0264131, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, objectType=article, longId=197998, objectId=2dca19e99888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dca19e99888, replyNumber=0, likeNumber=115, createdTime=2021-03-02, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dca19e99888, moduleTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dca19e99888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702661, encodeId=0bc81e0266188, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=205595, objectId=b9f020559582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9f020559582, replyNumber=0, likeNumber=82, createdTime=2021-09-14, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9f020559582, moduleTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9f020559582)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702649, encodeId=9fe61e0264903, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, objectType=article, longId=200687, objectId=397520068ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397520068ed0, replyNumber=0, likeNumber=66, createdTime=2020-11-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397520068ed0, moduleTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397520068ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702644, encodeId=c74e1e02644e8, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=94, createdTime=2021-03-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702655, encodeId=37121e0265541, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, objectType=article, longId=203701, objectId=4e38203e015a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e38203e015a, replyNumber=0, likeNumber=88, createdTime=2021-05-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e38203e015a, moduleTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e38203e015a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702646, encodeId=3e7f1e026460d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, objectType=article, longId=199756, objectId=08d0199e56b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08d0199e56b3, replyNumber=0, likeNumber=65, createdTime=2021-03-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08d0199e56b3, moduleTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08d0199e56b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702651, encodeId=72561e0265171, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤, objectType=article, longId=201135, objectId=43c4201135f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c4201135f9, replyNumber=0, likeNumber=72, createdTime=2021-03-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c4201135f9, moduleTitle=Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43c4201135f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702626, encodeId=20811e0262682, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, objectType=article, longId=193101, objectId=1e4d193101ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4d193101ba, replyNumber=0, likeNumber=94, createdTime=2020-09-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4d193101ba, moduleTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4d193101ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702642, encodeId=500f1e0264292, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=71, createdTime=2021-04-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702631, encodeId=d8751e02631be, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, objectType=article, longId=195473, objectId=16a61954e3e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a61954e3e1, replyNumber=0, likeNumber=91, createdTime=2021-04-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a61954e3e1, moduleTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16a61954e3e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702643, encodeId=d92c1e0264387, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, objectType=article, longId=198316, objectId=e83e198316b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e83e198316b3, replyNumber=0, likeNumber=65, createdTime=2020-10-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e83e198316b3, moduleTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e83e198316b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702620, encodeId=99251e02620c7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, objectType=article, longId=188100, objectId=0b4e188100f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4e188100f8, replyNumber=0, likeNumber=72, createdTime=2020-11-14, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4e188100f8, moduleTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4e188100f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clin Cancer Res：细胞周期蛋白D1依赖性转录程序可预测套细胞淋巴瘤患者的临床预后

2021-01-28

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：套细胞淋巴瘤亚型的基因组学和表观遗传学分析

2020-11-03

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-12-23

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析

2020-11-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：20号染色体缺失是乳房植入物相关间变性大细胞淋巴瘤的特征！

2021-09-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防

2021-01-15

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施

2021-03-24

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤

2020-12-28

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定

2021-03-02

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-09-14

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药

2020-11-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2021-03-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤

2021-05-23

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤

2021-03-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤

2021-03-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率

2020-09-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2021-04-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效

2021-04-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期

2020-10-24

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查

2020-11-14

科室
- - 订阅+
  - 更多科室
工具
服务